Literature DB >> 8239314

Synaptic pathology of Alzheimer's disease.

H Lassmann1, P Fischer, K Jellinger.   

Abstract

Prospective clinico-pathological studies on dementia in Alzheimer's disease (AD), performed during the past decades, revealed a relatively poor correlation between the degree of clinical deficit and the severity of the typical neuropathological lesions of AD, the amyloid plaques and the neurofibrillary tangles. More recent data, obtained by electron microscopy, immunocytochemical as well as immunochemical techniques indicate that synaptic loss may be a better structural correlate of dementia than other brain lesions. Synaptic pathology is reflected by a loss of all major components of small synaptic vesicles and most peptides, stored in large dense cored vesicles. The significant increase of chromogranin A proprotein, a major component of large dense cored vesicles, may rather represent a defect of protein processing than preservation of a specific synaptic subpopulation. Within the brain of AD patients, the degree of synaptic loss is uneven. Most prominent reduction of synapses is found in the outer parts of the dentate gyrus molecular layer, possibly reflecting the destruction of neurons, located in the layer 2 of the entorhinal cortex. However, within the neocortex, no preferential loss of synapses in any of the cortical layers has been found. Cerebral amyloid deposition in diffuse plaques has little effect on synapse density and structure. However, within the dense amyloid core of a classical plaque, synapses are completely lost. In the surrounding neuritic portion of the plaques, synaptophysin reactivity is frequently increased, due to enlargement of synaptic boutons and to accumulation of synaptophysin in dystrophic axons. Although the reason for synapse loss in AD is yet unknown, most results suggest that it may reflect degeneration of neurons, projecting into the respective cortical areas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8239314     DOI: 10.1111/j.1749-6632.1993.tb23028.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  21 in total

1.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

Review 2.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

3.  Spatial Training Ameliorates Long-Term Alzheimer's Disease-Like Pathological Deficits by Reducing NLRP3 Inflammasomes in PR5 Mice.

Authors:  Qing-Guo Ren; Wei-Gang Gong; Hong Zhou; Hao Shu; Yan-Juan Wang; Zhi-Jun Zhang
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

4.  Increasing CREB function in the CA1 region of dorsal hippocampus rescues the spatial memory deficits in a mouse model of Alzheimer's disease.

Authors:  Adelaide P Yiu; Asim J Rashid; Sheena A Josselyn
Journal:  Neuropsychopharmacology       Date:  2011-07-06       Impact factor: 7.853

5.  Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.

Authors:  Rawan Tarawneh; Gina D'Angelo; Dan Crimmins; Elizabeth Herries; Terry Griest; Anne M Fagan; Gregory J Zipfel; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  JAMA Neurol       Date:  2016-05-01       Impact factor: 18.302

6.  A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage.

Authors:  Sheng-Jia Zhang; Bettina Buchthal; David Lau; Stefanie Hayer; Oliver Dick; Markus Schwaninger; Roland Veltkamp; Ming Zou; Ursula Weiss; Hilmar Bading
Journal:  J Neurosci       Date:  2011-03-30       Impact factor: 6.167

7.  Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: the mitochondrial contribution.

Authors:  Yanfang Rui; Jiaping Gu; Kuai Yu; H Criss Hartzell; James Q Zheng
Journal:  Mol Brain       Date:  2010-03-26       Impact factor: 4.041

8.  NSAIDs may protect against age-related brain atrophy.

Authors:  Barbara B Bendlin; Lisa M Newman; Michele L Ries; Luigi Puglielli; Cynthia M Carlsson; Mark A Sager; Howard A Rowley; Catherine L Gallagher; Auriel A Willette; Andrew L Alexander; Sanjay Asthana; Sterling C Johnson
Journal:  Front Aging Neurosci       Date:  2010-09-03       Impact factor: 5.750

9.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

10.  Delayed amyloid plaque deposition and behavioral deficits in outcrossed AβPP/PS1 mice.

Authors:  Brian A Couch; Meghan E Kerrisk; Adam C Kaufman; Haakon B Nygaard; Stephen M Strittmatter; Anthony J Koleske
Journal:  J Comp Neurol       Date:  2013-04-15       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.